PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.71%
Some net income increase while CRVO is negative at -46.92%. John Neff would see a short-term edge over the struggling competitor.
-1.40%
Both reduce yoy D&A, with CRVO at -419.32%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-49.10%
Both cut yoy SBC, with CRVO at -100.00%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
5.95%
Less working capital growth vs. CRVO's 34.35%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.80%
Both negative yoy AP, with CRVO at -275.46%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
823.30%
Growth well above CRVO's 1563.51%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
59.87%
Growth of 59.87% while CRVO is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-19.06%
Negative yoy CFO while CRVO is 2.46%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
96.37%
CapEx growth of 96.37% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.44%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
92.69%
Debt repayment similar to CRVO's 100.00%. Walter Schloss sees parallel liability management or similar free cash flow availability.
-1494.87%
Both yoy lines negative, with CRVO at -54.24%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.